Literature DB >> 8996352

The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.

C H Bangma1, R Kranse, B G Blijenberg, F H Schröder.   

Abstract

PURPOSE: We analyzed the relationship between the free-to-total PSA ratio and prostate cancer tumor stage and grade compared to total serum PSA.
MATERIALS AND METHODS: In 123 patients clinical and pathological grade and stage were related to total serum PSA and free-to-total PSA ratio.
RESULTS: Total serum PSA paralleled clinical staging of prostate cancer. The distributions of total serum PSA and the free-to-total PSA ratio were significantly different between benign and malignant diseases (any stage), and between any T category and nodal disease. For serum PSA significant differences were noted between the distributions of men with locally confined (stages T1 and T2) and locally extended (stage T3) disease, and between all T categories and systemic metastatic disease. This finding was not noted for the free-to-total PSA ratio.
CONCLUSIONS: The free-to-total PSA ratio has no additional value in clinical staging of prostate carcinoma compared to serum PSA. The free-to-total PSA ratio may be considered the result of cell differentiation and not an indicator of tumor load.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8996352

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  Prostate cancer: a comprehensive review.

Authors:  S N Pentyala; J Lee; K Hsieh; W C Waltzer; A Trocchia; L Musacchia; M J Rebecchi; S A Khan
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

2.  The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml.

Authors:  Lorenzo Masieri; Andrea Minervini; Gianni Vittori; Michele Lanciotti; Federico Lanzi; Alberto Lapini; Marco Carini; Sergio Serni
Journal:  Int Urol Nephrol       Date:  2012-08       Impact factor: 2.370

3.  The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer.

Authors:  Güven Aslan; Bora Irer; Aykut Kefi; Ilhan Celebi; Kutsal Yörükoğlu; Adil Esen
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

4.  Improved discrimination of prostate cancer and benign prostatic hyperplasia by means of the quotient of free and total PSA.

Authors:  D Weckermann; C Maassen; F Wawroschek; R Harzmann
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.